Table 1 Characteristics of Studies and Participants
Figure captions
Figure 1 Flow chart
of study selection
Figure 2 Overall
survival (a), and progression-free survival (b), PD-L1 positive related
overall survival (c), and PD-L1 negative related overall survival (d)Figure 3 HPV
related overall survival (a), objective response rate (b), and HPV
related disease control rate (c)Figure 4 Any grade
(a) and grade ≥3 (b) adverse events of PD-1/PD-L1inhibitors alone groups Figure 5 Individual
analyses of any grade adverse events of PD-1/PD-L1 inhibitors alone
groupsFigure 6 Individual
analyses of grade ≥3 adverse events of PD-1/PD-L1 inhibitors alone
groups
Footnotes: PD-1: programmed death 1 receptor; PD-L1: programmed
death-ligand1; HPV: human papillomavirus; ECOG: Eastern Cooperative
Oncology Group. KEYNOTE-048 (1) represents the study involved PD-1/PD-L1
inhibitors alone groups versus control groups; KEYNOTE-048 (2)
represents the study involved PD-1/PD-L1 inhibitors with conventional
therapy groups versus control groups. REACH (1) represents the control
group as standard of care (cisplatin); REACH (2) represents the control
group as standard of care (cetuximab).
PD-L1 status was characterized by PD-L1 combined positive score (CPS)
calculated by the percentage of tumor cells, lymphocytes, and
macrophages in the amount of tumor cells (Burtness et al., 2019; Cohen
et al., 2019). PD-L1 was positive when PD-L1 CPS ≥1, otherwise PD-L1 was
negative.